

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2021; AND (2) APPOINTMENT OF NEW EXECUTIVE DIRECTOR

POLL RESULTS OF ANNUAL GENERAL MEETING

The Board is pleased to announce that at the AGM held on 18 June 2021, the Resolutions were duly passed as ordinary resolutions of the Company by the Shareholders by way of poll.

APPOINTMENT OF NEW EXECUTIVE DIRECTOR

The Board announces that Mr. Chu Xueping was appointed as an executive Director at the AGM with effect from 18 June 2021.

Reference is made to the circular (“**Circular**”) and notice (“**Notice**”) of the annual general meeting (“**AGM**”) of New Ray Medicine International Holding Limited (“**Company**”) dated 17 May 2021. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF ANNUAL GENERAL MEETING

The Board is pleased to announce that at the AGM held on 18 June 2021, all the resolutions as set out in the Notice (“**Resolutions**”) were duly passed as ordinary resolutions of the Company by the Shareholders by way of poll.

As at the date of the AGM, there were a total of 1,671,846,657 Shares in issue. To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, no Shareholder had material interest in the Resolutions and was required to abstain from voting on any of the Resolutions at the AGM in accordance with the Listing Rules. None of the Shareholders was entitled to attend and abstain from voting in favour of any of the Resolutions proposed at the AGM according to Rule 13.40 of the Listing Rules. None of the Shareholders stated his/her/its intention in the Circular to vote against any of the Resolutions or to abstain from voting at the AGM. As such, there were a total of 1,671,846,657 Shares, representing 100% of the issued share capital of the Company as at the date of the AGM, entitling holders thereof to attend and vote on the Resolutions proposed at the AGM.

The full text of the Resolutions was set out in the Notice, a copy of which is set out in the Circular. The poll results were as follows:

Ordinary Resolutions		Number of Shares (%)	
		For	Against
1.	To receive and approve the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and auditors of the Company for the year ended 31 December 2020.	502,416,000 (97.91%)	10,728,000 (2.09%)
2.	(a) To re-elect Ms. Wang Qiuqin as an executive Director.	437,520,000 (85.26%)	75,624,000 (14.74%)
	(b) To re-elect Mr. Huo Zhihong as an executive Director.	502,416,000 (97.91%)	10,728,000 (2.09%)
	(c) To re-elect Mr. Leung Chi Kin as an independent non-executive Director.	502,416,000 (97.91%)	10,728,000 (2.09%)
	(d) To re-elect Ms. Li Sin Ming, Ivy as an independent non-executive Director.	502,416,000 (97.91%)	10,728,000 (2.09%)
	(e) To re-elect Mr. Sy Lai Yin, Sunny as an independent non-executive Director.	502,416,000 (97.91%)	10,728,000 (2.09%)
	(f) To authorise the Board to fix the respective Directors' remuneration.	502,416,000 (97.91%)	10,728,000 (2.09%)
3.	To re-appoint Moore Stephens CPA Limited as the auditors of the Company for the year ending 31 December 2021 and to authorise the Board to fix its remuneration.	502,416,000 (97.91%)	10,728,000 (2.09%)
4.	To grant a general mandate to the Directors to allot, issue or otherwise deal with the Company's shares.	437,520,000 (85.26%)	75,624,000 (14.74%)
5.	To grant a general mandate to the Directors to repurchase the Company's shares.	502,416,000 (97.91%)	10,728,000 (2.09%)

Ordinary Resolutions		Number of Shares (%)	
		For	Against
6.	To extend the general mandate granted to the Directors to allot, issue or deal with the Company's shares by the number of shares repurchased.	437,520,000 (85.26%)	75,624,000 (14.74%)
7.	To appoint Mr. Chu Xueping as an executive Director.	437,520,000 (85.26%)	75,624,000 (14.74%)

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the AGM in person, by authorised corporate representative or by proxy.

As more than 50% of the votes were cast in favour of the Resolutions, the Resolutions were duly passed as ordinary resolutions of the Company by the Shareholders without modification at the AGM.

Tricor Investor Services Limited, the branch share registrar and transfer office of the Company in Hong Kong, was appointed as the scrutineer for the vote-taking at the AGM.

APPOINTMENT OF NEW EXECUTIVE DIRECTOR

The Board announces that Mr. Chu Xueping (“**Mr. Chu**”) was appointed as an executive Director at the AGM with effect from 18 June 2021.

The biographical details of Mr. Chu is set out below:

Mr. Chu, aged 49, is an executive Director. Mr. Chu graduated from Dalian Medical University (大連醫科大學) majoring in pharmacy in 1993. Mr. Chu has over 10 years of experience in the pharmaceutical industry in the PRC. Mr. Chu was the deputy general manager of 北京品尚品醫藥科技有限公司 (Beijing Pin Shang Pin Medicine Technology Co. Ltd., the English name is for identification purpose only) from 2011 to 2015 and the deputy president of Hainan Noken Pharmaceutical Co., Ltd. (海南諾爾康藥業有限公司) since 2016.

Pursuant to the service contract entered into between Mr. Chu and the Company, Mr. Chu has been appointed for a term of two years commencing on 18 June 2021 and is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the requirements of the Bye-laws. Mr. Chu is entitled to a salary of HK\$360,000 per annum under the service contract which was determined by the Board with reference to his background, experience, qualifications, duties and responsibilities within the Group and the prevailing market condition and is entitled to a discretionary performance bonus as may be determined by the Board.

As at the date of this announcement, Eagle Amber Holdings Limited (“**Eagle Amber**”), a substantial shareholder of the Company, held 426,672,000 ordinary shares of the Company, representing approximately 25.52% of the total issued shares of the Company. Mr. Chu beneficially owned 30% of the total issued shares of Eagle Amber.

As at the date of this announcement, save as disclosed above, Mr. Chu (i) did not hold other positions with the Company or other members of the Group; (ii) did not have any relationship with any Director, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules) of the Company; (iii) did not hold any other major appointment and professional qualifications; (iv) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (v) did not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Chu that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Mr. Chu to join the Company.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 18 June 2021

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.

Note: Trading in the Shares has been suspended with effect from 9:00 a.m. on 6 October 2017 by the Stock Exchange as directed by the Securities and Futures Commission in accordance with its direction issued under Section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V, the Laws of Hong Kong). Trading in the Shares will remain suspended until further notice. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.